DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Review, H2 2016

Publisher Name :
Date: 31-Aug-2016
No. of pages: 46

DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, ‘DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Review, H2 2016', provides in depth analysis on DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1)

- The report reviews DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Review, H2 2016

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) Overview 6
Therapeutics Development 7
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Products under Development by Stage of Development 7
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Products under Development by Therapy Area 8
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Products under Development by Indication 9
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Products under Development by Companies 12
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Therapeutics Assessment 14
Assessment by Monotherapy/Combination Products 14
Assessment by Mechanism of Action 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Companies Involved in Therapeutics Development 20
Celgene Corporation 20
Eli Lilly and Company 21
Merck KGaA 22
Onxeo SA 23
Vertex Pharmaceuticals Incorporated 24
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Drug Profiles 25
AsiDNA - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
CC-115 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
LY-3023414 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
M-3814 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
VX-984 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Dormant Projects 33
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Discontinued Products 34
DNA Dependent Protein Kinase Catalytic Subunit (DNAPK1 or p460 or PRKDC or EC 2.7.11.1) - Featured News & Press Releases 35
Jul 04, 2016: Onxeo receives USPTO Notice of Allowance for key AsiDNA patent, extending IP protection in the U.S. until 2031 35
Jul 04, 2016: Onxeo receives USPTO Notice of Allowance for key AsiDNATM patent, extending IP protection in the U.S. until 2031 36
Jun 27, 2016: Onxeo advances development plan for first-in-class signal interfering DNA compound AsiDNA 37
Jun 17, 2015: Eli Lilly and Company Enters Into Strategic Partnership with Sarah Cannon Research Institute to Develop Investigational Oncology Therapy 38
May 30, 2015: DNA Therapeutics presents encouraging results for first-in-class pan DNA repair inhibitor 38
Mar 05, 2014: Curie-Cancer and DNA Therapeutics partner in the fight against cancers that resist conventional therapies 39
Mar 26, 2012: DNA Therapeutics Announces Completion Of Two First Dose Escalations In DRIIM Trial 41
Jan 10, 2012: DNA Therapeutics Announces USPTO's Decision To Grant Third Dbait Patent 42
Jan 03, 2012: DNA Therapeutics Announces Completion Of Two Week Course Of Patients In First Cohort Of DRIIM Trial 42
Jan 03, 2012: DNA Therapeutics Announces Completion Of Two Week Course Of Treatment Of Patients In First Dose Cohort Of DRIIM Trial 43
Nov 25, 2011: DNA Therapeutics's Dbait Receives Chinese Patent Allowance For Treatment Of Metastatic Melanoma 43
Aug 22, 2011: DNA Therapeutics Receives Clinical Trial Authorization From French Competent Authority For DNA Therapeutics' First-In-Human Trial 44
Mar 31, 2011: DNA Therapeutics Completes Regulatory Toxicology Studies Of DT01 In Rat And Monkey 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables
Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Action, H2 2016 15
Number of Products by Stage and Route of Administration, H2 2016 17
Number of Products by Stage and Molecule Type, H2 2016 19
Pipeline by Celgene Corporation, H2 2016 20
Pipeline by Eli Lilly and Company, H2 2016 21
Pipeline by Merck KGaA, H2 2016 22
Pipeline by Onxeo SA, H2 2016 23
Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 24
Dormant Projects, H2 2016 33
Discontinued Products, H2 2016 34

List of Figures
Number of Products under Development for, H2 2016 7
Number of Products under Development by Top 10 Indication, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 11
Assessment by Monotherapy/Combination Products, H2 2016 14
Number of Products by Stage and Mechanism of Actions, H2 2016 15
Number of Products by Routes of Administration, H2 2016 16
Number of Products by Stage and Routes of Administration, H2 2016 16
Number of Products by Molecule Types, H2 2016 18
Number of Products by Stage and Molecule Type, H2 2016 18
  • Europe Restriction Endonucleases Market by Manufacturers, Countries, Type and Application, Forecast to 2022
    Published: 21-Jul-2017        Price: US 4480 Onwards        Pages: 119
    Restriction Endonuclease is an enzyme that cuts DNA at or near specific recognition nucleotide sequences known as restriction sites. They are the enzymes that are found in the bacteria and are harvested from them for their use in research and commercial aspects. Restriction enzymes are commonly classified into four types, which differ in their structure and whether they cut their DNA substrate at their recognition site, or if the recognition and cleavage sites are separate from one another.......
  • Asia-Pacific Protein Hydrolysis Enzymes Market Report 2017
    Published: 20-Jul-2017        Price: US 4000 Onwards        Pages: 106
    In this report, the Asia-Pacific Protein Hydrolysis Enzymes market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Protein Hydrolysis Enzymes for these regions, from 2012 to 2022 (forecast), including - China - Japan - So......
  • Global Lipase Sales Market Report 2017
    Published: 20-Jul-2017        Price: US 4000 Onwards        Pages: 104
    In this report, the global Lipase market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Lipase for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Southeast Asia......
  • Asia-Pacific Enzymes Market Report 2017
    Published: 20-Jul-2017        Price: US 4000 Onwards        Pages: 119
    In this report, the Asia-Pacific Enzymes market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split Asia-Pacific into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Enzymes for these regions, from 2012 to 2022 (forecast), including - China - Japan - South Korea - Taiwan - Ind......
  • Global Protein Hydrolysis Enzymes Market Research Report 2017
    Published: 20-Jul-2017        Price: US 2900 Onwards        Pages: 103
    In this report, the global Protein Hydrolysis Enzymes market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Protein Hydrolysis Enzymes in these regions, from 2012 to 2022 (forecast), covering - North America - Europe......
  • EMEA (Europe, Middle East and Africa) Glucoamylase Market Report 2017
    Published: 19-Jul-2017        Price: US 4000 Onwards        Pages: 116
    In this report, the EMEA Glucoamylase market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K MT) , revenue (Million USD) , market share and growth rate of Glucoamylase for these regions, from 2012 to 2022 (forecast) - Europe: Germany, France, UK, Russia, Italy and Benelux; - Middl......
  • Global Kinase Inhibitors Sales Market Report 2017
    Published: 19-Jul-2017        Price: US 4000 Onwards        Pages: 101
    In this report, the global Kinase Inhibitors market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units) , revenue (Million USD) , market share and growth rate of Kinase Inhibitors for these regions, from 2012 to 2022 (forecast) , covering - United States - China - Europe - Jap......
  • Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Pipeline Review, H2 2017
    Published: 18-Jul-2017        Price: US 3500 Onwards        Pages: 30
    Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary Serine/Threonine Protein Kinase A Raf (Proto Oncogene A Raf or Proto Oncogene Pks or ARAF or EC 2.7.11.1) pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies. The latest report SerineThreonine Protein Kinase A Raf - Pipeline Review, H2 2017, outlays comprehensive i......
  • Global (North America, Europe and Asia-Pacific, South America, Middle East and Africa) Phytases Market 2017 Forecast to 2022
    Published: 18-Jul-2017        Price: US 4880 Onwards        Pages: 115
    This report studies the Phytases market, A phytase (myo-inositol hexakisphosphate phosphohydrolase) is any type of phosphatase enzyme that catalyzes the hydrolysis of phytic acid (myo-inositol hexakisphosphate) - an indigestible, organic form of phosphorus that is found in grains and oil seeds - and releases a usable form of inorganic phosphorus.Scope of the Report:This report focuses on the Phytases in Global market, especially in North America, Europe and Asia-Pacific, S......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs